EyePoint Pharmaceuticals, Inc.
EYPT
$14.52
$0.836.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -205.75M | -175.38M | -146.78M | -130.87M | -103.57M |
| Total Depreciation and Amortization | 2.08M | 1.91M | 1.73M | 1.54M | 1.19M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.33M | 23.42M | 24.84M | 30.88M | 27.85M |
| Change in Net Operating Assets | -30.57M | -40.54M | -27.97M | -27.77M | -38.95M |
| Cash from Operations | -210.91M | -190.59M | -148.18M | -126.23M | -113.49M |
| Capital Expenditure | -2.68M | -3.45M | -3.13M | -4.05M | -4.55M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 49.96M | 11.55M | -197.50M | -215.30M | -165.99M |
| Cash from Investing | 47.28M | 8.10M | -200.64M | -219.36M | -170.54M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -110.00K | -156.00K | -140.00K | -105.00K | -73.00K |
| Issuance of Common Stock | 160.51M | 164.99M | 165.34M | 169.31M | 235.75M |
| Repurchase of Common Stock | -1.37M | -1.32M | -1.37M | -4.51M | -4.51M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -656.00K | -656.00K | -874.00K | -672.00K | -343.00K |
| Cash from Financing | 158.38M | 162.87M | 162.96M | 164.02M | 230.82M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.25M | -19.63M | -185.86M | -181.56M | -53.21M |